Data from smartphones and wearable devices may help with the early detection of idiopathic pulmonary arterial hypertension (IPAH), a rare lung disease with no known cause, a study suggests. Using up to eight years of data obtained via the My Heart Counts iOS app, device-derived data helped distinguish…
News
Building on positive data from an earlier study, Allrock Bio has dosed the first patients in a small clinical trial testing ROC-101, its oral treatment candidate for pulmonary hypertension (PH). The open-label Phase 2a ROCSTAR study (NCT07175038) is recruiting patients across the U.S., Canada, and Europe — including…
Children with pulmonary hypertension (PH) engage in fewer and shorter bouts of intense physical activity than their peers, according to a new study that measured data from sensors worn on the wrist. Moreover, kids with more severe PH generally had “worse physical testing,” as well as “a steeper decline…
The first participant has been enrolled in a two-part Phase 3 clinical trial testing IKT-001, Inhibikase Therapeutics’ experimental formulation of imatinib, in people with pulmonary arterial hypertension (PAH). The Phase 3 IMPROVE-PAH trial (NCT07365332) is expected to enroll nearly 500 adults with various forms of PAH, ages 18…
Patients with interstitial lung diseases (ILDs) who require supplemental oxygen are more than three times as likely to experience pulmonary hypertension (PH), according to new interim data from the PHINDER study. The findings reveal that this serious complication is frequently missed by doctors, who correctly identified PH in 60%…
Anumana‘s AI-enabled algorithm for the early detection of pulmonary hypertension (PH) has been cleared for use by the U.S. Food and Drug Administration (FDA). “The FDA clearance of our Pulmonary Hypertension algorithm is the result of rigorous clinical development and regulatory work, and it marks a meaningful step…
Treatment with CS1, a once-daily oral therapy being developed by Cereno Scientific, was found to be safe and well tolerated for people with pulmonary arterial hypertension (PAH), according to one-year data from an expanded access program (EAP). The EAP (NCT06321705), also known as compassionate use in the…
In a large clinical trial, treatment with Winrevair (sotatercept-csrk) significantly reduced pressure in the lungs’ blood vessels among adults with a form of pulmonary hypertension associated with heart failure, according to newly published data. The injection therapy, approved in the U.S. for…
A history of smoking was associated with worse survival outcomes in male patients with pulmonary arterial hypertension (PAH), according to a new study. The analysis found, however, that smoking history did not significantly affect survival in female PAH patients or in people with chronic thromboembolic pulmonary hypertension (CTEPH).
The proportion of people in the U.S. with pulmonary arterial hypertension related to the use of methamphetamine (Meth-PAH) increased by 93% between 2018 and 2022, a steeper increase than the one seen for the number of U.S. adults self-reporting methamphetamine use, a new study shows. The analysis found that Meth-PAH patients…
Winrevair (sotatercept-csrk), an injection therapy approved for adults with pulmonary arterial hypertension (PAH), is now covered by several of Canada’s publicly funded health programs. The therapy’s developer Merck, known as MSD outside the U.S. and Canada, announced that Winrevair has been added to the public drug formularies…
Measuring levels of tiny pieces of genetic material in the blood, known as microRNAs, may help identify group 2 pulmonary hypertension (PH), according to a new study. “We identified a set of circulating [microRNAs] that are differentially expressed in Group 2 PH and correlated with disease severity,” researchers wrote…
